MELBOURNE, Australia<\/span> and INDIANAPOLIS<\/span><\/span>, June 7, 2022<\/span><\/span> \/PRNewswire\/ – Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) a biopharmaceutical company focused on the development and commercialisation of diagnostic and therapeutic products using Molecularly Targeted Radiation (MTR) advises that Dr Christian Behrenbruch<\/span>, Group CEO and Managing Director will be presenting at the Jefferies Healthcare Conference in New York<\/span>.<\/p>\n

\n<\/p><\/div>\n

The presentation will take place on June 10<\/span><\/span> at 11.30am ET<\/span>. A live webcast of the presentation will be available at this link https:\/\/wsw.com\/webcast\/jeff240\/tlx\/1721400<\/a>. A replay will be made available on the Telix website.<\/p>\n

About <\/b>Telix Pharmaceuticals Limited <\/b><\/p>\n

Telix is a biopharmaceutical company focused on the development and commercialisation of diagnostic and therapeutic products using Molecularly Targeted Radiation (MTR). Telix is headquartered in Melbourne, Australia<\/span> with international operations in Belgium<\/span>, Japan<\/span>, Switzerland<\/span>, and the United States<\/span>. Telix is developing a portfolio of clinical-stage products that address significant unmet medical need in oncology and rare diseases. Telix is listed on the Australian Securities Exchange (ASX: TLX). For more information visit www.telixpharma.com<\/a> and follow Telix on Twitter<\/a> (@TelixPharma) and LinkedIn<\/a>.<\/p>\n

Telix’s lead product, gallium-68 (^{68<\/sup>Ga) gozetotide (also known as ^{68<\/sup>Ga PSMA-11) injection, has been approved by the U.S. Food and Drug Administration (FDA),^{[1]<\/sup> and by the Australian Therapeutic Goods Administration (TGA).^{[2]<\/sup> Telix is also progressing marketing authorisation applications for this investigational candidate in Europe<\/span>^{[3]<\/sup> and Canada<\/span>.^{[4]<\/sup><\/p>\n}}}}}}

Telix Investor Relations
<\/b>Ms. Kyahn Williamson
Telix Pharmaceuticals Limited
SVP Corporate Communications and Investor Relations
Email: kyahn.williamson@telixpharma.com<\/a><\/p>\n

U.S. Contact
<\/b>Lisa Wilson<\/span>
In-Site Communications, Inc.
Email: lwilson@insitecony.com<\/a><\/span>
T: 917-543-9932<\/p>\n

\n\n\n\n\n\n\n
\n
[1] ASX disclosure 20 December 2021.<\/span><\/p>\n<\/td>\n<\/tr>\n
\n
[2] ASX disclosure 2 November 2021.<\/span><\/p>\n<\/td>\n<\/tr>\n
\n
[3] ASX disclosure 10 December 2021.<\/span><\/p>\n<\/td>\n<\/tr>\n
\n
[4] ASX disclosure 16 December 2020.<\/span><\/p>\n<\/td>\n<\/tr>\n<\/tbody>\n<\/table><\/div>\n
Legal Notices<\/p>\n
This announcement may include forward-looking statements that relate to anticipated future events, financial performance, plans, strategies or business developments. Forward-looking statements can generally be identified by the use of words such as "may", "expect", "intend", "plan", "estimate", "anticipate", "outlook", "forecast" and "guidance", or other similar words. Forward-looking statements involve known and unknown risks, uncertainties and other factors that may cause our actual results, levels of activity, performance or achievements to differ materially from any future results, levels of activity, performance or achievements expressed or implied by these forward-looking statements. Forward-looking statements are based on the Company’s good-faith assumptions as to the financial, market, regulatory and other considerations that exist and affect the Company’s business and operations in the future and there can be no assurance that any of the assumptions will prove to be correct. In the context of Telix’s business, forward-looking statements may include, but are not limited to, statements about: the initiation, timing, progress and results of Telix’s preclinical and clinical studies, and Telix’s research and development programs; Telix’s ability to advance product candidates into, enrol and successfully complete, clinical studies, including multi-national clinical trials; the timing or likelihood of regulatory filings and approvals, manufacturing activities and product marketing activities; the commercialisation of Telix’s product candidates, if or when they have been approved; estimates of Telix’s expenses, future revenues and capital requirements; Telix’s financial performance; developments relating to Telix’s competitors and industry; and the pricing and reimbursement of Telix’s product candidates, if and after they have been approved. Telix’s actual results, performance or achievements may be materially different from those which may be expressed or implied by such statements, and the differences may be adverse. Accordingly, you should not place undue reliance on these forward-looking statements. <\/i><\/p>\n
To the maximum extent permitted by law, Telix disclaims any obligation or undertaking to publicly update or revise any forward-looking statements contained in this announcement, whether as a result of new information, future developments or a change in expectations or assumptions. <\/i><\/p>\n
The Telix Pharmaceuticals name and logo are trademarks of Telix Pharmaceuticals Limited and its affiliates (all rights reserved). <\/i><\/p>\n
<\/div>\n","protected":false},"excerpt":{"rendered":"
MELBOURNE, Australia and INDIANAPOLIS, June 7, 2022 \/PRNewswire\/ – Telix Pharmaceuticals Limited (ASX: TLX, Telix, the Company) a biopharmaceutical company focused on…<\/p>\n","protected":false},"author":1,"featured_media":0,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[105],"tags":[],"acf":[],"_links":{"self":[{"href":"https:\/\/staging.fnarena.com\/index.php\/wp-json\/wp\/v2\/posts\/102066"}],"collection":[{"href":"https:\/\/staging.fnarena.com\/index.php\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/staging.fnarena.com\/index.php\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/staging.fnarena.com\/index.php\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/staging.fnarena.com\/index.php\/wp-json\/wp\/v2\/comments?post=102066"}],"version-history":[{"count":0,"href":"https:\/\/staging.fnarena.com\/index.php\/wp-json\/wp\/v2\/posts\/102066\/revisions"}],"wp:attachment":[{"href":"https:\/\/staging.fnarena.com\/index.php\/wp-json\/wp\/v2\/media?parent=102066"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/staging.fnarena.com\/index.php\/wp-json\/wp\/v2\/categories?post=102066"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/staging.fnarena.com\/index.php\/wp-json\/wp\/v2\/tags?post=102066"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}